Cohance lifesciences Limited has announced a key leadership appointment, naming Mr. Sisir K. Mishra as Company Secretary, Compliance Officer and Key Managerial Personnel. The appointment was approved by the Board of Directors at their meeting held on March 30, 2026, following recommendations from the Nomination and Remuneration Committee.

Appointment Details

The new appointment will be effective from April 9, 2026. Mr. Mishra holds membership number F8555 with the Institute of Company Secretaries of India and will assume multiple critical roles within the organization's governance structure.

Professional Background

Mr. Sisir K. Mishra brings substantial expertise to his new role at Cohance Lifesciences Limited. He is a Fellow Member of the Institute of Company Secretaries of India and holds an LL.M. from Osmania University. His professional experience spans over two decades in corporate secretarial, legal, governance, CSR and ESG functions across diversified sectors.

Key Experience Areas

Mr. Mishra's expertise encompasses several critical business functions:

• Board governance and regulatory interface management
• Mergers and acquisitions oversight
• Fundraising and IPO readiness preparation
• Compliance management systems implementation
• Corporate social responsibility and ESG initiatives

Previous Professional Experience

Prior to joining Cohance Lifesciences Limited, Mr. Mishra served as Company Secretary with several prominent organizations. His previous roles include positions at NCC Limited, Paradeep Phosphates Limited, Deccan Cements Limited and KSK Group, among others. This diverse experience across infrastructure, manufacturing, IT and power sectors positions him well for his new responsibilities.

Regulatory Compliance

The appointment has been made in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has fulfilled all disclosure requirements as mandated by SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. The appointment reflects the company's commitment to maintaining robust governance standards and regulatory compliance.

Cohance lifesciences Limited has announced a significant employee stock option grant, with its Nomination and Remuneration Committee approving the allocation of 1,98,711 stock options to eligible employees under the Employee Stock Option Plan 2023 (ESOP 2023). The decision was made during the committee meeting held on March 13, 2026.

Stock Option Grant Details

The comprehensive stock option grant encompasses several key parameters designed to align employee interests with company performance:

Vesting and Exercise Framework

The stock options operate under a structured timeline designed to promote long-term employee retention:

The Nomination and Remuneration Committee retains discretionary authority to modify vesting schedules, provided such changes do not adversely impact employee interests and comply with applicable laws.

Regulatory Compliance and Documentation

This stock option grant fulfills disclosure requirements under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has structured the ESOP 2023 in accordance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, ensuring full regulatory compliance.

The announcement was signed by Himanshu Agarwal, Whole-time Director and Chief Financial Officer, emphasizing the strategic importance of this employee benefit initiative. Detailed terms and conditions of the stock options are available in the ESOP 2023 document on the company's official website.

Strategic Implications

This stock option grant represents Cohance Lifesciences' commitment to employee engagement and retention through equity participation. The flexible vesting period of 1-10 years allows the company to tailor incentives based on individual employee roles and performance expectations, while the 3-year exercise window provides sufficient time for employees to make informed decisions regarding their equity participation.